A Novel Inactivated Vaccine Based on an Emerging PEDV GIIc Variant Provides Cross-Protection Against Heterologous GII Strains

TL;DR

A new inactivated vaccine based on an emerging PEDV strain offers strong protection against different variants of the virus in piglets.

Contribution

A novel inactivated vaccine using an emerging PEDV GIIc variant provides cross-protection against heterologous GII strains.

Findings

The PEDV-HeN2024 strain caused severe disease in neonatal piglets.

Vaccinated piglets showed potent cross-neutralizing activity against multiple PEDV strains.

Vaccinated animals were protected from clinical disease and maintained normal intestinal architecture.

Abstract

Background/Objectives: Porcine epidemic diarrhea virus (PEDV), particularly the emerging GII genotype, poses a severe threat to the swine industry in affected regions, primarily in Asia. Current vaccines based on classical strains often provide limited cross-protection against these heterogeneous variants, though it should be noted that these vaccines are primarily designed to induce maternal immunity in sows. The objective of this study was to develop a novel inactivated vaccine using an emerging PEDV GIIc variant and evaluate its immunogenicity and cross-protective efficacy against heterologous strains. Methods: A novel PEDV strain, designated PEDV-HeN2024, was isolated from clinical samples and identified through cell culture, immunofluorescence assay (IFA), genetic sequencing, and phylogenetic analysis. An inactivated vaccine was prepared by emulsifying the purified virus with ISA 201 VG adjuvant (1:1, v/v). Immunogenicity was assessed in piglets by measuring virus-neutralizing antibody titers and PEDV-specific IgG levels. Cross-protective efficacy was evaluated through in vitro neutralization assays and in vivo challenge studies with homologous GIIc and heterologous GIIa and GIIb strains. Results: The isolated PEDV-HeN2024 strain demonstrated pathogenicity, causing severe diarrhea and 100% mortality in PEDV-naïve neonatal piglets. Sera from vaccinated animals showed potent cross-neutralizing activity against homologous GIIc, as well as heterologous GIIa and GIIb strains. In challenge studies, vaccinated piglets were significantly protected against clinical disease, showing no diarrhea or viral shedding, and maintained normal intestinal architecture. Conclusions: The inactivated vaccine developed from the emerging PEDV GIIc variant elicits robust humoral immunity and provides cross-protection against prevalent heterologous GII strains. These findings highlight its potential as a promising spectrum vaccine candidate for controlling PEDV outbreaks. This study underscores the importance of using recently circulating strains for vaccine development to overcome the limitations of current vaccines.

Figures

Full text

1. Introduction

Porcine epidemic diarrhea virus (PEDV), a member of the Coronaviridae family, can cause disease in susceptible pigs of various ages, although it is most severe in neonatal piglets, leading to substantial economic losses in the global swine industry [1]. Since its initial identification in the 1970s, PEDV has evolved into multiple genotypes, with the emerging GI (classical) and GII (variant) strains becoming dominant in recent outbreaks [2]. Among these, the GII genotype, particularly the GIIa, GIIb, and GIIc subgroups, has shown increased virulence and antigenic variability, posing significant challenges to existing vaccine strategies [3,4]. Current commercial vaccines, primarily based on classical GI strains (such as CV777), have demonstrated limited efficacy against emerging GII variants due to antigenic drift and poor cross-neutralization [5,6]. Although several inactivated and attenuated vaccines derived from GIIa strains have been developed, their protective scope remains narrow, often failing to elicit broad immune responses against heterologous GIIb and GIIc variants [7]. This immunological gap underscores the urgent need for novel vaccine candidates that can address the ongoing genetic divergence of PEDV.

The PEDV genome is approximately 28 kb in length and consists of a 5′ cap structure, a 3′ poly(A) tail, and at least seven open reading frames (ORFs), namely ORF1a, ORF1b, S, ORF3, E, M, and N genes [8]. These ORFs encode four structural proteins (spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins), sixteen nonstructural proteins (NSPs), and one accessory protein, ORF3 [9]. The S protein, located on the surface of the virion, is the largest structural protein and can induce the production of neutralizing antibodies [10]. The PEDV S gene can be classified into three genotypes: GI, GII, and S-Indel. Variations such as nucleotide substitutions, deletions, or insertions in the S gene occur among different PEDV strains [11]. Consequently, the S gene is frequently used as a target for molecular epidemiological and phylogenetic analyses of PEDV. Recent studies have highlighted the critical role of the spike (S) protein in mediating viral entry and neutralizing antibody responses [12,13]. Phylogenetic analyses of circulating strains in China (2020–2022) indicate that GIIc variants have become increasingly prevalent, with distinct mutations in the S gene receptor-binding domain potentially contributing to immune evasion [14]. However, few studies have focused on the development of GIIc-based vaccines, and their cross-protective potential against other prevalent genotypes remains unexplored.

In this study, we isolated and characterized a novel PEDV strain, designated PEDV-HeN2024, belonging to the GIIc subgroup. This strain demonstrated pathogenicity in neonatal piglets (3–5 days old and PEDV-naive herds), causing severe enteric pathology and high viral shedding. We further developed an inactivated vaccine using this strain adjuvanted with ISA 201 VG and evaluated its immunogenicity and cross-protective efficacy.

2. Materials and Methods

2.1. Cells and Viruses

Vero cells (ATCC CCL-81) were purchased from BeNa Culture Collection (Xinyang, China). The cells were cultured in Gibco™ DMEM (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% Gibco™ fetal calf serum (Thermo Fisher Scientific, Waltham, MA, USA) and Gibco™ penicillin/streptomycin antibiotics (100 U/mL penicillin, 100 mg/mL streptomycin; Thermo Fisher Scientific, Waltham, MA, USA). The cells were maintained at 37 °C, 5% CO_2_, and 90% relative humidity. The PEDV-GIIa and PEDV-GIIb strains were isolated and preserved by our laboratory.

2.2. Virus Isolation and Propagation

The intestinal contents or fecal samples from piglets with severe watery diarrhea were collected from a swine farm in China. The samples were homogenized, centrifuged, and filtered through a 0.22 μm filter. The filtrate was inoculated onto confluent monolayers of Vero cells (ATCC CCL-81) maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10 μg/mL trypsin (TPCK-treated) and 5% fetal bovine serum (FBS) at 37 °C in a 5% CO_2_ incubator. After 1 h of adsorption, the inoculum was removed, and fresh maintenance medium was added. The cells were monitored daily for cytopathic effects (CPEs). Blind passages were performed until stable CPEs (syncytium formation and cell detachment) were observed [2,7].

Plaque Purification: When the cell density in the 6-well plate reached approximately 90%, a plaque assay was performed. The virus was diluted in DMEM, inverted, and vortexed twice. The pipette tip was changed, and the nutrient solution in the 6-well plate was aspirated and discarded in two steps. Subsequently, 1 mL of virus-containing DMEM was added to the wells at dilutions ranging from 10^−7^ to 10^−2^. The plate was incubated for 2 h and gently shaken every 20 min. Agar was melted in a water bath 1 h in advance, and both the melted agar and 2× DMEM (supplemented with 2% serum, pH = 7.6) were placed in a 37 °C water bath 0.5 h prior to use. A mixture of 2% low-melting-point agarose and 2× DMEM was prepared at a 1:1 ratio, with 14 mL of each combined in a 50 mL centrifuge tube. After aspirating the virus-containing DMEM from the wells (10^−7^ to 10^−2^), 2 mL of the mixed agarose was added to each well and allowed to solidify at room temperature for 0.5 h. Once solidified, the plate was transferred to a 5% CO_2_ incubator at 37 °C for 72–96 h. When distinct plaques became visible, the plate was removed, stained with crystal violet solution for 12 h at room temperature, rinsed under running water to remove the agarose, and plaque morphology was observed.

50% Tissue Culture Infective Dose (TCID_50_) Assay: On the appearance of significant cytopathic effects (CPEs), the collected viral supernatant was titrated. Vero cells were seeded into a 96-well cell culture plate one day prior to the assay. On the day of the assay, the viral solution was serially diluted two-fold in DMEM containing 10 μg/mL trypsin, ranging from 10^−1^ to 10^−8^. The supernatant of confluent Vero cell monolayers in the 96-well plate was discarded, and the cells were washed twice with PBS. The diluted viral solution was then inoculated into the cell culture plate, with eight parallel replicates per dilution, and 100 μL of viral solution was added per well. Normal cells were used as a blank control, with 100 μL of DMEM containing 10 μg/mL trypsin added per well. After 5–7 days of incubation, CPE was observed, and the data were analyzed using the Reed–Muench method [15].

2.3. Virus Identification and Characterization

Immunofluorescence Assay (IFA): Vero cells infected with the isolated virus were fixed with 80% acetone. The cells were then incubated with a porcine anti-PEDV-specific antibody (MEDIAN Diagnostics, Chuncheon-si, Gangwon-do, Republic of Korea) for 1 h at 37 °C, followed by incubation with a FITC-conjugated goat anti-pig IgG antibody (1:200 dilution; Sigma-Aldrich, St. Louis, MO, USA). The nuclei were stained with DAPI. The cells were visualized under a fluorescence microscope (Nikon Eclipse Ti2, Nikon Instruments Inc., Tokyo, Japan).

Genetic Sequencing and Phylogenetic Analysis: Viral RNA was extracted from the cell culture supernatant using TRIzol LS Reagent (Invitrogen, Carlsbad, CA, USA). The full-length spike (S) gene was amplified by RT-PCR using specific primers (S1-Forward: 5′-AGATTGCTCTACCTTATACCTG-3′, S1-Reverse: 5′-GAAAGAACTAAACCCATTGATA-3′; S2-Forward: 5′-AGCCAACTCAAGTGTTCTCAGG-3′, S2-Reverse: 5′-AGCCACAGTGTTCAAACCCTT-3′; S3-Forward: 5′-TTAATAAAGTGGTTACTAATGGC-3′, S3-Reverse: 5′-ATAATAAAGAGCGCATTTTTATA-3′). The amplified products were purified and sequenced (Sangon Biotech, Shanghai, China). A phylogenetic tree was constructed using the complete nucleotide sequence of the spike (S) gene. Phylogenetic analysis was performed based on the complete nucleotide sequence of the spike (S) gene, which is the standard genomic region used for PEDV genotyping. Reference sequences of different genotypes (GI, S-Indel, GII) were downloaded from GenBank.

2.4. Animal Challenge Studies

All animal experiments were approved by the Animal Welfare and Ethics Committee (AWEC) of ShenLian Bio-medicine (Shanghai) Co., Ltd., Shanghai, China. (Approval No: 2025003-1 and 2025009-1) and were conducted in accordance with relevant guidelines and regulations.

All piglets were sourced from specific pathogen-free (SPF) herds with confirmed PEDV-naive status. Specific pathogen-free (SPF) piglets from two age groups (3–5 days old, n = 3; 28–30 days old, n = 3) were orally inoculated with 10 mL of the fifth-passage virus stock (10^5^ TCID_50_). A control group (n = 3 for each age group) was inoculated with an equal volume of sterile PBS. Clinical signs (diarrhea, vomiting, lethargy) were recorded daily. Fecal swabs were collected daily for viral RNA detection by RT-PCR targeting the PEDV N gene. At 5 days post inoculation (dpi), all piglets were euthanized for necropsy. Intestinal tissues were collected for histopathological examination and viral load quantification.

For cross-protection evaluation, piglets were challenged with 10^5^ TCID_50_ of GIIa (strain HuN2016), GIIb (strain MSCH2020) and GIIc (strain HeN2024) strains via oral inoculation. Clinical signs and viral shedding were monitored daily for 7 days post-challenge.

2.5. Vaccine Preparation and Immunization

The isolated PEDV-GIIc virus was propagated, inactivated with 0.1% binary ethylenimine (BEI) at 37 °C for 24 h, and confirmed to be completely inactivated by three blind passages in Vero cells. The inactivated antigen was emulsified with ISA 201 VG adjuvant (Seppic) at a ratio of 1:1 (v/v) to form a Water-in-Oil-in-Water (W/O/W) emulsion.

Twenty-one 3–5-day-old SPF piglets were randomly divided into three groups (n = 3 per group): Group 1 (Our vaccine): immunized intramuscularly with 2 mL of the inactivated vaccine. Group 2 (Commercial Vaccine): immunized intramuscularly with 2 mL of the inactivated vaccine. The commercial vaccine’s instruction manual indicated that the antigen component was the complete inactivated strain of PEDV GIIa. Additionally, the commercial vaccine employed in this study is indicated for use in piglets. The product insert explicitly states that it is suitable for vaccinating piglets, with a recommended regimen of one dose per animal followed by a booster vaccination after a 14-day interval, due to commercial confidentiality agreements, the precise product name, antigen dose, and adjuvant formulation cannot be disclosed; Group 3 (Placebo Control): inoculated with 2 mL of PBS emulsified with ISA 201 VG adjuvant (1:1); and Group 4 (Blank Control): inoculated with 2 mL of PBS (Table 1). A booster immunization was administered with the same formulation 14 days later.

2.6. Serological Assay

Sera were collected at 0, 14, 21, 28, and 35 days post immunization (dpi). Virus Neutralization (VN) Assay: Serum samples were serially diluted two-fold and mixed with an equal volume of 200 TCID_50_ of PEDV strains (GIIa, GIIb, and GIIc). The mixture was incubated and then added to Vero cell monolayers. The neutralizing antibody titer was calculated as the highest serum dilution that completely inhibited CPE [16].

Enzyme-Linked Immunosorbent Assay (ELISA): PEDV-specific total antibodies (IgG) in serum were detected using a commercial PEDV Antibody Test Kit (Lanzhou Shou yan Biotechnology Co., Ltd., Lanzhou, China) according to the manufacturer’s instructions.

2.7. Statistical Analysis

All data were expressed as mean ± standard deviation (SD). Statistical significance was determined by one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test using GraphPad Prism 9.0. A p-value < 0.05 was considered statistically significant.

3. Results

3.1. Virus Isolation and Genetic Characterization

A novel PEDV strain was successfully isolated from the clinical samples using Vero cells. The two processed intestinal homogenates (Intestine-1 and Intestine-2) were identified by RT-PCR (Figure S1A). The results showed that, compared with the positive control, both samples produced a specific band of approximately 830 bp. The culture supernatant harvested after five serial blind passages in Vero cells was also analyzed by RT-PCR. As shown in Figure S1B, with properly functioning negative and positive controls, the amplified products exhibited bands of the expected size. This indicates that the PEDV isolate obtained from the processed intestinal homogenate was stably passaged from passages 1 to 5 (P1–P5). After four blind passages, typical cytopathic effects (CPEs), characterized by syncytium formation and cell detachment, were consistently observed (Figure 1A). Subsequent plaque purification was performed on the F5 viral harvest originating from intestinal sample 2. After three rounds of purification, a single clone exhibiting the fastest growth was selected as the seed virus (Figure S1C). To further verify the viral identity, an immunofluorescence assay (IFA) was performed. The assay utilized a monoclonal antibody that specifically targets the spike (S) protein of PEDV, which yielded positive results, thereby confirming the virus’s identity. Robust fluorescence signals were observed in the cytoplasm of virus-infected Vero cells, whereas no signal was detected in mock-infected cells (Figure 1B). The isolated virus was designated as PEDV-HeN2024.

Genetic characterization based on the complete spike (S) gene sequence (GenBank accession no. PX470115) was performed. Sequence alignment revealed that our isolate harbored the signature insertions and deletions in the S gene characteristic of variant strains, distinguishing it from classical CV777-like strains Further analysis of the S gene sequence revealed characteristic amino acid substitutions and deletions within the receptor-binding domain compared to the classical CV777 strain and other prevalent GII strains, which may influence antigenicity. Phylogenetic analysis demonstrated that PEDV/HeN2024 clustered within the GIIc genogroup, which has been increasingly reported in China since 2020. Notably, it formed a distinct branch with other recently emerged GIIc strains, indicating its status as a new and evolving variant within this genogroup (Figure 1C,D). While the primary genetic characterization focused on the S gene, preliminary analysis of the complete genome sequence did not reveal evidence of recombination events with other common porcine coronaviruses under the parameters examined. Future work will include a more comprehensive recombination analysis across other genomic regions.

3.2. Pathogenicity of PEDV/HeN2024/GIIc in Piglets

The pathogenicity of the PEDV/HeN2024/GIIc isolate was evaluated in both neonatal (3–5 days old) and weaned (28–30 days old) specific-pathogen-free (SPF) piglets. All inoculated piglets in both age groups developed severe clinical signs, including watery diarrhea and vomiting, within 24–48 h post inoculation (hpi) (Table 2). The clinical disease was notably more acute in neonatal piglets. Consistent with field observations of variant PEDV strains, 100% mortality (n = 3/3) was observed in the neonatal group by 96 hpi (Figure 2A). In contrast, weaned piglets showed significant morbidity (e.g., severe diarrhea, lethargy, anorexia) but no mortality, highlighting the age-dependent susceptibility to PEDV (Table 2). And the attenuated pathogenicity observed in the weaned piglets (~31 days old) may compromise the rigorous assessment of protective efficacy, particularly against heterologous challenges. Consequently, we have emphasized that the protection claims in this age group should be interpreted with caution. No clinical signs were observed in the PBS-inoculated control groups throughout this study. High levels of viral shedding were detected via RT-qPCR in fecal swabs collected from all challenged piglets, starting from 1 day post inoculation (dpi) and persisting until the endpoint of the experiment (for weaned piglets) or death (for neonates) (Figure 2B,C). Viral RNA copies in feces peaked at around 2–4 dpi.

Postmortem examination of dead piglets revealed lesions characteristic of severe PEDV infection. The small intestines, particularly the duodenum and jejunum, were thin-walled, transparent, and distended with yellow, watery fluid (Figure S2). Histopathological analysis (H&E staining) of the duodenum and jejunum from infected piglets revealed villus atrophy and degeneration of intestinal epithelial cells compared to the control groups (Figure 3). These findings confirm the enteropathogenicity of the PEDV/HeN2024/GIIc isolate.

3.3. Immunogenicity of the Inactivated Vaccine

The inactivated vaccine formulated with ISA 201 VG adjuvant (1:1 ratio) induced robust humoral immune responses in immunized piglets. Virus-neutralizing (VN) antibody titers and PEDV-specific IgG antibody levels were measured weekly (Figure 4A). From 21 days post immunization (dpi) onwards, the geometric mean titers (GMTs) of virus-neutralizing (VN) antibodies and the concentrations of IgG antibodies in the vaccinated group were significantly higher than those in the placebo (adjuvant-only) group, the blank control group (p < 0.01), and the commercial vaccine group. The VN antibody titers in the vaccinated group continued to rise until the challenge study at 28 dpi, indicating a strong and sustained immune response elicited by the vaccine (Figure 4B,C).

3.4. Cross-Protective Efficacy Against Heterologous Challenges

The key finding of this study was the cross-neutralizing activity elicited by the GIIc-based inactivated vaccine. At 28 days post immunization, serum samples were tested for neutralization activity in vitro. The sera demonstrated potent neutralizing activity against both the homologous GIIc strain (PEDV/HeN2024/GIIc) and heterologous GIIa and GIIb strains. Notably, the neutralizing antibody titers against all tested strains were significantly higher than those elicited by the commercial vaccine. The sera effectively neutralized all three tested strains, with the highest GMT observed against the homologous virus (Figure 5A). This result demonstrated the induction of cross-reactive neutralizing antibodies. But the comparison with the commercial vaccine was conducted in vitro at the serological level, serving as a preliminary assessment of immune response magnitude rather than aiming to mimic complex mucosal or maternal immunity.

The PEDV-HeN2024 vaccine conferred significant protection against clinical disease upon challenge with all three genotypes (GIIa, GIIb, and GIIc); the absence of diarrhea and fecal viral shedding served as the primary endpoints for efficacy evaluation. Following heterologous viral challenges (with GIIa and GIIb strains), piglets in the vaccinated group exhibited significant protection: they showed no clinical signs, and significantly reduced viral shedding in feces was detected via RT-qPCR (Figure 5B). Histopathological examination of the jejunum post-challenge revealed well-preserved intestinal villus structures in the vaccinated group, in marked contrast to the villus atrophy observed in the control groups (Figure 5C).

4. Discussion

The continuous emergence of PEDV variants, particularly within the GII genogroup, poses a significant and ongoing challenge to the global swine industry [2,19,20]. Vaccination remains the most effective strategy for controlling PED; however, the efficacy of existing commercial vaccines, often based on classical or earlier variant strains, is frequently compromised against these emerging variants due to antigenic differences [21,22]. In this study, we successfully isolated a novel PEDV strain, identified it as a GIIc variant through comprehensive genetic and phylogenetic analyses, and developed an inactivated vaccine that demonstrated immunogenicity and cross-protective efficacy against homologous and heterologous (GIIa, GIIb) challenges.

Our phylogenetic analysis confirmed that the isolated strain, PEDV-HeN2024, clusters with recently emerging GIIc strains but occupies a distinct branch, suggesting ongoing viral evolution [23]. This genetic divergence is a primary driver of the suboptimal protection offered by existing vaccines, as mutations, especially in the S protein, the major target of neutralizing antibodies, can lead to antigenic drift and immune evasion [24,25]. The pathogenicity of our isolate was unequivocally demonstrated in both neonatal and weaned piglets. The 100% mortality in neonatal piglets and significant morbidity in weaned piglets align with the severe clinical manifestations reported in outbreaks caused by contemporary variants, underscoring the urgent need for effective countermeasures [5,26,27]. It is important to note that a key limitation of this study is the small group size (n = 3) used in the animal experiments, which affects the statistical power and generalizability of the findings. The study is therefore more appropriately considered a proof-of-concept investigation rather than a definitive efficacy trial. The sample size was selected based on the exploratory nature of this initial investigation and constraints related to the availability of specific-pathogen-free (SPF) piglets meeting the stringent age requirements.

The cornerstone of our findings is the remarkable cross-protective ability induced by the GIIc-based inactivated vaccine. Sera from vaccinated animals potently neutralized not only the homologous GIIc virus but also heterologous GIIa and GIIb strains in vitro. This was further corroborated by in vivo challenge studies: vaccinated piglets challenged with all three genotypes (GIIa, GIIb, GIIc) exhibited significant protection, with no clinical symptoms and substantially reduced viral shedding, and maintained normal intestinal architecture. This spectrum protection is likely attributable to the presentation of conserved antigenic epitopes shared among the contemporary GII variants by our vaccine strain [7]. By utilizing a recently circulating GIIc variant as the vaccine seed, we may have elicited a broader and more relevant immune response compared to vaccines based on older strains. This finding is critically important, as it suggests that updating vaccine strains to match currently prevalent variants can overcome the limitations of cross-protection [28,29]. But the cross-protection observed is against the specific genotypes tested and that efficacy against a wider range of circulating strains requires further investigation. We have also acknowledged that the use of naive piglets does not fully represent the complex immune status of herds in endemic areas. We now state that future studies should evaluate the vaccine’s efficacy in sows to assess its impact on maternal-derived immunity (MDA) and protection in piglets, which is the primary goal of PEDV vaccination in the field.

Our results are consistent with and extend the findings of other research groups focusing on PEDV variants. For instance, Li et al. highlighted the role of nonstructural proteins, such as nsp1, in the immune evasion mechanisms of variant strains, which may explain the virulence of our isolate, and while a protective vaccine is the ultimate goal, selecting a vaccine strain that is antigenically well-matched to circulating field strains is one strategy to potentially enhance the breadth [30,31] and potency of the immune response, especially given the genetic diversity of PEDV [20,32,33,34]. In addition, antigen concentration and adjuvants are equally critical factors.

While our inactivated vaccine candidate shows great promise, several aspects warrant further investigation. First, the duration of immunity conferred by this vaccine needs to be evaluated in a long-term study, especially in sows, to assess the level and persistence of maternal antibodies transferred to piglets [6,13]. Second, exploring the vaccine’s efficacy in a prime-boost regimen, potentially combining it with a live-attenuated vaccine, could further enhance the strength and breadth of the immune response [35,36,37]. Furthermore, the challenge strain of porcine epidemic diarrhea virus (PEDV) exhibited attenuated pathogenicity in older piglets [38]. Our results indicated that 31-day-old piglets challenged with the virus exhibited only mild, transient clinical diarrhea, which complicated the assessment of protective efficacy. Finally, investigating the specific conserved epitopes responsible for cross-neutralization could guide the development of even more effective next-generation vaccines, such as subunit or epitope-based vaccines [39].

In conclusion, we have developed a novel inactivated vaccine based on an emerging PEDV GIIc variant. This vaccine elicits neutralizing antibodies and provides cross-protection against the predominant heterologous GII (GIIa, GIIb, GIIc) strains currently in circulation, and its efficacy against more distantly related strains requires further investigation. Our study underscores the importance of continuous viral surveillance and the timely development of vaccines based on prevalent strains as a viable strategy to control the devastating losses caused by PEDV variants in the swine industry.

This study has certain limitations that should be considered when interpreting the results. The primary limitation is the relatively small group size (n = 3 per group), which was constrained by the availability of specific-pathogen-free (SPF) piglets meeting the stringent age requirements and the exploratory nature of this initial investigation. This affects the statistical power and generalizability of the findings. Furthermore, while control groups (Placebo Control: ISA 201 VG; Blank Control: PBS) were included for the immunization and homologous challenge study, the heterologous challenge experiments focused on evaluating the vaccine group against internal baselines rather than including separate control groups for each heterologous challenge due to animal use constraints. Consequently, the scientific relevance of this work is limited by these experimental design constraints, and the validity and relevance of the findings should be interpreted with caution. To build upon these promising preliminary findings, we are currently conducting additional animal experiments with larger sample sizes and more comprehensive control group designs. Once these results are available, we plan to report them in subsequent, more comprehensive manuscripts that are well-prepared from the outset.